[Suppression of synthesis of tumor necrosis factor].
Eigler
A
A
Abteilung für Klinische Pharmakologie, Medizinische Klinik Innenstadt, Klinikum der Ludwig-Maximilians-Universität München.
Loher
F
F
Endres
S
S
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology; D003424:Crohn Disease / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology*; D016753:Interleukin-10 / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D020889:Rolipram / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013792:Thalidomide / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology
D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D013792:Thalidomide; D020889:Rolipram